89bio Profit Margin

89bio (ETNB) currently reports a profit margin of -2143838.1% as of June 2025. That compares with -74620.51% in the prior-year period — down 2773.0% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore 89bio's profit margin history and peer comparisons.

89bio's profit margin decreased from -74620.51% to -2143838.1% — a 2773.0% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

89bio's profit margin of -2143838.1% is lower than the Healthcare sector average of 15.29%. That is roughly 14018631.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but 89bio's current -2143838.1% should be judged against Healthcare norms (sector average: 15.29%) and against ETNB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2143838.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for 89bio, and consider following ETNB for alerts when major investors trade the stock.